These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 30796122

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM, IMPROVE-CKD Trial Investigators.
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [Abstract] [Full Text] [Related]

  • 3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V, Longhitano E, Calabrese V, Casuscelli C, Di Carlo S, Spinella C, Gembillo G, Santoro D.
    Expert Opin Pharmacother; 2023 Nov; 24(15):1737-1746. PubMed ID: 37527180
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB, Martin KJ.
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [Abstract] [Full Text] [Related]

  • 10. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
    Vermeulen EA, Eelderink C, Hoekstra T, van Ballegooijen AJ, Raijmakers P, Beulens JW, de Borst MH, Vervloet MG.
    Trials; 2022 Sep 12; 23(1):769. PubMed ID: 36096824
    [Abstract] [Full Text] [Related]

  • 11. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND, Pedagogos E, Tan SJ, Badve SV, Hawley CM, Perkovic V, Elder GJ.
    Nephrology (Carlton); 2012 Jul 12; 17(5):433-44. PubMed ID: 22574672
    [Abstract] [Full Text] [Related]

  • 12. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L, Liu A, Xu G.
    Ren Fail; 2021 Dec 12; 43(1):1378-1393. PubMed ID: 34602015
    [Abstract] [Full Text] [Related]

  • 13. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P, Prié D, Keddad K, Preston P, Wilde P, Wan H, Copley JB.
    BMC Nephrol; 2014 May 05; 15():71. PubMed ID: 24885942
    [Abstract] [Full Text] [Related]

  • 14. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
    Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.
    Am J Nephrol; 2013 May 05; 38(2):158-67. PubMed ID: 23941761
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y, Matsuda Y, Takahashi S, Shigematsu T, Lanthanum Carbonate Study Group.
    Clin Nephrol; 2014 Sep 05; 82(3):181-90. PubMed ID: 25079863
    [Abstract] [Full Text] [Related]

  • 16. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.
    J Am Soc Nephrol; 2019 Jun 05; 30(6):1096-1108. PubMed ID: 31085679
    [Abstract] [Full Text] [Related]

  • 17. The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.
    Bressendorff I, Hansen D, Schou M, Kragelund C, Brandi L.
    BMJ Open; 2017 Jun 23; 7(6):e016795. PubMed ID: 28645983
    [Abstract] [Full Text] [Related]

  • 18. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I, Haffner D, Leifheit-Nestler M.
    Toxins (Basel); 2019 Nov 06; 11(11):. PubMed ID: 31698866
    [Abstract] [Full Text] [Related]

  • 19. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N, Angeliki Veroniki A, Thabane L, Busse JW, Akhtar-Danesh N, Iorio A, Cruz Lopes L, Guyatt GH.
    PLoS One; 2017 Nov 06; 12(3):e0171028. PubMed ID: 28248961
    [Abstract] [Full Text] [Related]

  • 20. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE, ANSWER Study Organization.
    Am J Kidney Dis; 2019 Sep 06; 74(3):338-350. PubMed ID: 31027883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.